Volcker, Greenspan, Bernanke, and Yellen contribute to a Wall Street Journal op-ed on monetary policy independence.

Olivia London

2019-09-23 12:25:00 Mon ET

Volcker, Greenspan, Bernanke, and Yellen contribute to a Wall Street Journal op-ed on monetary policy independence. These former Federal Reserve chiefs unite together to express their core concern that Fed Chair Jerome Powell institutes the recent dovish interest rate decrease in response to a vocal president. In their joint conviction, the Federal Reserve and its chair must be able to make monetary policy decisions in the best interests of the U.S. economy. Further, these monetary policy decisions must be independent and free of short-term political pressure without the threat of either removal or demotion of Federal Reserve leaders for non-economic reasons. Volcker, Greenspan, Bernanke, and Yellen emphasize the congressional checks and balances with respect to the Federal Reserve monetary policy purview.

In recent times, Fed Chair Jerome Powell and FOMC members approve a quarter-point interest rate decrease to help sustain the current U.S. economic expansion. This monetary policy decision arises in the broader context of relentless criticisms among the Trump hawkish hardliners. The hardliners and President Trump himself view the prior U.S. interest rate hikes as headwinds that may inadvertently offset the economic benefits of Trump tax incentives and other fiscal stimulus packages for better infrastructure, investment, and technology.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

We assess the global fiscal deficits and sovereign debt burdens in America, Europe, and many other countries worldwide.

James Campbell

2027-01-31 12:25:00 Sunday ET

We assess the global fiscal deficits and sovereign debt burdens in America, Europe, and many other countries worldwide.

In recent decades, many governments have chosen to run high fiscal deficits on top of sovereign debt mountains so that greater government intervention still

+See More

Apple, Alphabet, Microsoft, Amazon, and Facebook have become the most valuable public companies in the world.

Olivia London

2017-05-13 07:28:00 Saturday ET

Apple, Alphabet, Microsoft, Amazon, and Facebook have become the most valuable public companies in the world.

America's Top 5 tech firms, Apple, Alphabet, Microsoft, Amazon, and Facebook have become the most valuable publicly listed companies in the world. These

+See More

Jim Cramer provides 5 key reasons against the purchase and use of cryptocurrencies such as Bitcoin, Ethereum, and Ripple.

Becky Berkman

2017-11-23 10:42:00 Thursday ET

Jim Cramer provides 5 key reasons against the purchase and use of cryptocurrencies such as Bitcoin, Ethereum, and Ripple.

As the TV host of Mad Money, Jim Cramer provides 5 key reasons against the purchase and use of cryptocurrencies such as Bitcoin. First, no one knows the ano

+See More

Corporate payout management

Fiona Sydney

2022-05-05 09:34:00 Thursday ET

Corporate payout management

Corporate payout management This corporate payout literature review rests on the recent survey article by Farre-Mensa, Michaely, and Schmalz (2014). Out

+See More

The semiconductor microchip demand-supply imbalance remains severe for American big tech.

Amy Hamilton

2022-05-30 09:32:00 Monday ET

The semiconductor microchip demand-supply imbalance remains severe for American big tech.

The new semiconductor microchip demand-supply imbalance remains quite severe for the U.S. tech and auto industries.  Our current fundamental macro a

+See More